N the United States, the estimated incidence of transmission of malaria by blood transfusion (less than 1 case per million units collected 1 ) is less than that of hepatitis B virus (7 to 32 cases per million units) and bacterial infections (e.g., 1 case of platelet-related sepsis per 12,000 units 2 ) and is similar to that of hepatitis C or human immunodeficiency virus after the introduction of nucleic acidtesting techniques. 3 There are few data on the risk of transfusion-transmitted babesiosis 4 (approximately 6 cases per million units). 5 Since there is no approved laboratory test in the United States to screen donated blood for malaria, prevention depends on the exclusion of potentially in-I fected donors who are identified during the donor interview. The Food and Drug Administration (FDA) 6, 7 and the American Association of Blood Banks 8 have recommendations for the exclusion of potentially infected donors (Table 1) . However, it can be difficult to obtain accurate travel and immigration histories and to ascertain the areas of a country in which malaria is transmitted.
From 1996 through 1998, three cases of transfusion-transmitted malaria occurred, two of which were fatal. 9 To gain a better understanding of how to prevent such cases, we reviewed the epidemiologic features of cases of transfusion-transmitted malaria in the United States, as reported to the Centers for Disease Control and Prevention (CDC) from 1963 (the first year complete records were available) through 1999.
METHODS
Information about the patients was obtained from reports of cases of malaria sent to the National Malaria Surveillance System at the CDC, which include information on demographic characteristics, date of the onset of illness, species responsible for the infection, history of travel or blood transfusion, type of antimalarial therapy, and outcome of the illness. Because malaria infections acquired in the United States are further investigated by the CDC (in conjunction with state or local health departments), further details on transfusion-transmitted cases were obtained by reviewing the annual malaria-surveillance summaries of the CDC. During the epidemiologic investigations that ensue after a case is detected, an attempt is made to collect serum from the donors involved so that it can be tested at the CDC for antimalarial antibodies by the indirect fluorescence antibody assay. 10 Antibody titers of 1:64 or more are considered positive and to indicate previous or current infection. When possible, donors are reinterviewed regarding their travel history, any prior diagnosis of malaria, country of birth, and date of entry into the United States, and a blood smear is obtained and reviewed at the CDC. We considered a donor to be the source of the malaria infection if at least one of three criteria was met: the donor had a positive blood smear; the donor had a positive serologic test result; or the patient had received blood from no other donor.
In general, when a case of transfusion-transmitted malaria occurs, any remaining blood components from potentially infective donors are withheld from transfusion pending evaluation of the donors. Once an infective donor is identified, any recipient of his or her blood components (from the same or a prior donation) is evaluated for malaria.
The cases of transfusion-transmitted malaria we reviewed occurred over a period of years, during which donor-exclusion guidelines changed several times (Table 1) . During this time, the guidelines evolved to provide specific durations of deferral; a diagnosis of malaria now requires a three-year deferral instead of a permanent exclusion, and the deferral period for travelers is now the same whether or not they have received chemoprophylaxis. To determine the suitability of donors implicated in these cases, we reviewed the reported epidemiologic characteristics of each donor in the light of the current FDA exclusion guidelines (defined as those issued in 1994) and those in effect at the time of donation. The incidence of transfusion-transmitted malaria in the United States was calculated as the number of cases divided by the number of units of *In 1994, the FDA continued to recommend a three-year deferral for persons who had had malaria, whereas the American Association of Blood Banks during 1994 through 1996 recommended deferring such persons indefinitely. In 1996, the American Association of Blood Banks returned to recommending a three-year deferral for such persons. The 1994 guidelines of the FDA were used for donor-suitability analyses in this article. †The guidelines proposed by the FDA in 2000 are currently in draft form.
cent from 1963 through 1979 to 27 percent from 1980 through 1999 (P<0.001).
Ten of the 93 patients (11 percent) died. Patients who died were significantly older than those who survived (mean, 71 vs. 47 years; P<0.001; range, 53 to 85 years and 2 days to 78 years, respectively). Six of the patients who died had P. falciparum infection, two had P. vivax, and two had P. malariae. The reported cause of death of the two patients infected with P. vivax was the underlying disease. The reported cause of death of the two patients with P. malariae infection involved unusually high densities of parasites, although the specific densities were unknown. The incubation period was available in 57 cases (Table 2 ). In 43 cases for which data were available, the number of days from the onset of symptoms to the diagnosis of malaria ranged from 1 to 180 (median, 10).
Implicated Donors
There were a presumed 91 infective donors for the 93 patients (in two different episodes, 2 patients had the same donor). In 67 of the 91 episodes (74 percent), an infective donor could be identified. Fiftythree of 59 donors (90 percent) whose sex was reported were male. In 37 cases in which information was available, the implicated donors' ages ranged from 19 to 59 years (median, 27); 78 percent were 21 to 40 years old. In 64 cases, the country of origin of the implicated donor was known. Twenty-six (41 percent) were born in the United States, and 38 (59 percent) were born in other countries (24 in Africa, 4 in Asia, 6 in the Americas, and 4 in Europe). The proportion of implicated donors in the past 20 years who were former residents of countries where malaria was endemic (86 percent) was significantly greater than the proportion from 1963 through 1979 (26 percent, P<0.001) ( Table 3) .
Forty-eight of the 67 implicated donors were identified by serologic tests (72 percent), 7 by blood smear (10 percent), 10 by both serologic tests and blood smear (15 percent), and 2 by the sole-donor criterion (3 percent). Serologic tests were positive in 58 of 59 implicated donors in which testing was performed (98 percent); a blood smear showed malaria parasites in 17 of 49 donors in which it was performed (35 percent).
There was enough information in the records to permit a judgment to be made as to whether the donor should have been excluded according to current exclusion criteria in 60 cases and according to prior exclusion criteria in 48 cases. Thirty-seven of 60 donors (62 percent) should have been excluded according to current FDA guidelines, and 30 of 48 (62 percent) according to the guidelines in place at the time of donation. The species distributions for cases in which current guidelines were followed and those in which they were not are shown in Table 4 . Of the 15 P. malariae infections that occurred when current guidelines were followed, 12 were due to foreignborn donors and 3 to U.S.-born donors. The time *A listing of all cases, with details on the year, the number of donors involved, demographic characteristics and travel or immigration history of the implicated donor, laboratory results, and compliance with donor-deferral guidelines is available from the authors. †Values in parentheses are the numbers of cases with data on the incubation period. between the donor's immigration to the United States or last foreign travel to a malarious area and blood donation ranged from 3 to 44 years (median, 8).
T ABLE 2. T HE C AUSATIVE S PECIES
Of the four P. falciparum infections that occurred even though current guidelines had been followed, one was due to a foreign-born donor who had immigrated (more than the 3-year deferral period). The remaining three were due to U.S.-born donors; the time between their last travel to a malarious area and blood donation ranged from 1 to 5 years (median, 13 months).
The implicated donors in two cases of P. vivax malaria had been born in the United States but had subsequently United States for one year before donation, and the other for two years. One case caused by P. ovale was associated with a U.S.-born donor who had lived in Liberia for several years but who had reportedly last been in a malarious area four years before donating blood. The implicated donor in a case of mixed infection had reportedly last been in a malarious area seven years before donating.
Trends in the Incidence of Transfusion-Transmitted Malaria
The incidence of transfusion-transmitted malaria in the United States has decreased in the past three decades and now remains at a stable low level (Fig. 1) . From 1965 through 1970, the incidence rate ranged from 0 to 1.37 cases per million units transfused; from 1993 through 1998, the incidence rate ranged from 0 to 0.18 case per million units transfused. The peak in cases of transfusion-transmitted malaria in the late 1960s and early 1970s was associated with the return cases of malaria reported in the United States, largely (54) 0 0 ciation of Blood Banks modified its uniform donorscreening questionnaire in 1999. 21 Blood-bank personnel inquire generally about travel outside the United States or Canada within the previous three years (instead of relying on donors to report whether they have been in a malarious area) and then probe to determine whether travel was to a malarious area. To improve the assessment of such donors, the FDA has recently proposed that donors first be asked whether they were born in the United States. 7 If they were not, they are asked when they moved to the United States and whether they have traveled outside the United States since their arrival. Approximately one third of the cases of transfusion-transmitted malaria occurred despite adherence to current guidelines. The donor-exclusion criteria have their scientific basis in the biologic behavior of the different plasmodium species. Infections with species that cause relapsing illness (P. vivax and P. ovale) rarely persist longer than three years. 22 Infections with P. falciparum rarely persist longer than one or two years, 1 and 99 percent of patients present within one year of departure from a malarious area. 23 National malaria-surveillance data from 1985 through 1997 included 7407 reported cases in U.S.-born residents and 6252 in foreign-born residents. Among 5737 cases in U.S.-born residents for which information was available, 119 cases (2.1 percent) had their onset more than one year after the patient had traveled to a malarious area. Among 4229 cases in foreign-born residents for which information was available, 7 cases (0.2 percent) had their onset more than three years after the patient left a malarious area. In U.S. surveillance data, we found transfusion-transmitted cases of P. vivax, P. ovale, and P. falciparum infections in which donors had reportedly left malarious areas five, seven, and nine years, respectively, before the diagnosis of malaria in the recipient. We also found 9 case reports in the literature of transfusion-transmitted infections by species other than P. malariae with more than three years between the donor's departure from a malarious area and the diagnosis of malaria in the recipient or the transfusion.
The longest periods between the reported exposure to malaria and the donation of blood products that transmitted the infection were 13 years in the case of a P. falciparum infection, 24 27 years in the case of a P. vivax infection, 24 and 7 years in the case of a P. ovale infection. 25 In our series, the longest interval between travel to a malarious area and transmission of malaria through a blood transfusion was 44 years in the case of a P. malariae infection, 5 years in the case of a P. falciparum infection, 2.5 years in the case of a P. vivax infection, and 7 years in the case of a P. ovale infection. Because P. malariae parasites can persist for decades, 26-28 rare cases of transfusion-transmitted malaria will continue to occur despite the use of current exclusion guidelines. The guidelines aim to strike a balance between minimizing the risk of malaria and excluding as few uninfected donors as possible.
One possible option for reducing transfusion-transmitted malaria is laboratory screening. Among potential screening tests, diagnosis on the basis of a bloodsmear examination is not sensitive enough, since donors who have transmitted the infection typically have a low level of parasitemia 22 that may not be detected even by careful examination of a blood smear. In their current stage of development, antigen-detection tests 29, 30 have an even higher limit of detection (in terms of the number of parasites per cubic millimeter) than blood-smear examination and would be of limited usefulness in screening. The incidence is the number of cases per 1,000,000 units of whole blood and packed red cells transfused. 0 10 1 9 6 3 1 9 6 4 1 9 6 5 1 9 6 6 1 9 6 7 1 9 6 8 1 9 6 9 1 9 7 0 1 9 7 1 1 9 7 2 1 9 7 3 1 9 7 4 1 9 7 5 1 9 7 6 1 9 7 7 1 9 7 8 1 9 7 9 1 9 8 0 1 9 8 1 1 9 8 2 1 9 8 3 1 9 8 4 1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 
